Overview

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Status:
Withdrawn

Trial end date:
2017-07-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines